Veeva Pulse Report Finds Content-Driven Engagement Lags Despite Proven Boost to Treatment Adoption
Content effectiveness, not creation, is the goal that drives highest impact PLEASANTON, Calif., May 29, 2025 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today... Read more.
Callan Promotes Uvan Tseng to Lead Its West Coast Consulting Team
SAN FRANCISCO, May 29, 2025 /PRNewswire/ — Callan, a leading institutional investment consulting firm, announced today that Uvan Tseng, CFA, has been promoted... Read more.
Trevi Therapeutics to Participate in Upcoming June Conferences
NEW HAVEN, Conn., May 29, 2025 /PRNewswire/ — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational... Read more.
Strand Capital Launches Inaugural $250M Fund Leveraging Proprietary Analytics to Transform Single-Family Rental Investing
Technology Designed to Cut Investment Return Timeline in Half While Targeting Underserved Markets SCOTTSDALE, Ariz., May 29, 2025 /PRNewswire/ — Strand Capital,... Read more.
China, ASEAN and GCC Advance Cooperative Frameworks to Strengthen Regional Supply Chain Resilience
KUALA LUMPUR, Malaysia, May 29, 2025 /PRNewswire/ — China, the Association of Southeast Asian Nations (ASEAN) and the Gulf Cooperation Council (GCC) are ramping... Read more.
AKAS Launches Full-Chain Protocol to Redefine Decentralized Ownership and Governance
TÓRSHAVN, Denmark, May 29, 2025 /PRNewswire/ — AKAS announces the official launch of its full-chain upgraded protocol—made to usher in a new era of collective... Read more.
FBS Leads the Way with the Best Trading Conditions 2025 Award
SINGAPORE, May 29, 2025 /PRNewswire/ — FBS, a leading global broker, proudly announces a significant achievement — the title of Best Trading Conditions 2025,... Read more.
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
NEW YORK, May 29, 2025 /PRNewswire/ — Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing... Read more.
Lumeris and MIT Computational Biology Lab Partner to Solve America’s 2 Billion Hour Primary Care Gap
Collaboration advances AI-driven Primary Care as a Service™ through next-gen computational models ST. LOUIS, May 29, 2025 /PRNewswire/ — Lumeris, a leader... Read more.
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson’s Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor
BHV-8000 is a first-in-clinic, brain-penetrant, and selective inhibitor of TYK2 and JAK1 kinases — a novel investigational therapy with the potential to treat... Read more.